Stay informed with our curated selection of industry articles, offering the latest insights and trends in drug development and clinical trials. Explore the latest trends, research breakthroughs, and industry updates to keep you informed.
February 2025
Replacing Anecdotal With Empirical Evidence On Impact of DCTs | Ken Getz | Applied Clinical Trials
Description: In this article, Tufts CSDD Executive Director Ken Getz discusses the shift from anecdotal reports to empirical evidence regarding the impact of decentralized clinical trials (DCTs). He highlights recent findings from the PACT Consortium, showing that DCT components such as virtual visits, remote data collection, and home visits are improving patient recruitment, retention, and diversity in clinical trials. The data also indicates that trials using DCT solutions experience faster enrollment timelines and greater representation of underrepresented groups, such as Asian and Indigenous participants, compared to traditional clinical trials. Read more: https://www.appliedclinicaltrialsonline.com/view/replacing-anecdotal-with-empirical-evidence-on-impact-of-dcts
January 2025
Quantifying Site Burden to Optimize Protocol Performance | Maria Florez, Zachary Smith, Zachary Olah, Mike Martin, Kenneth Getz | The Drug Information Association, Inc.
Description: The introduction of Decentralized Clinical Trials—trials supported by remote and virtual technologies and services—is expected to impact the burden imposed on sites, but this impact has not yet been systematically measured. Access the article: https://link.springer.com/article/10.1007/s43441-023-00602-5
May 2024
Examining the Association Between DCT Solutions Use and Participant Diversity in Clinical Trials | Zachary Smith, Kenneth Getz | The Drug Information Association, Inc.
Description: Whereas anecdotal reports suggest that the use of decentralized clinical trial (DCT) solutions can improve participant diversity in clinical trials, there is no quantitative evidence to support such reports. Tufts CSDD conducted an initial study to compare and contrast participant diversity in trials, including various DCT solutions – virtual visits or televisits, home visits, devices or wearables, and local labs. Read more here: https://link.springer.com/article/10.1007/s43441-024-00659-w
September 2024
The Relationship Between Participant Diversity and DCT Use in Clinical Trials | Ken Getz | Applied Clinical Trials
Description: Tufts CSDD Executive Director Ken Getz delves into the crucial connection between participant diversity and decentralized clinical trials (DCTs). He explores how DCTs can break down barriers to participation, ensuring that clinical research better represents diverse populations. With a growing push for inclusivity in healthcare, this piece highlights the potential of DCTs to drive more equitable, accessible, and generalizable clinical trial outcomes. Access the full article here: https://www.appliedclinicaltrialsonline.com/view/relationship-between-participant-diversity-and-dct-in-clinical-trials
June 2023
Optimizing the Process for Adopting DCT Solutions | Ken Getz | Applied Clinical Trials
Description: Tufts CSDD Executive Director Ken Getz delves into the complexities of integrating decentralized clinical trial (DCT) solutions, outlining strategies to optimize the adoption process. It examines key challenges, practical approaches, and considerations for organizations transitioning to DCT models in clinical research. Access the full article: https://www.appliedclinicaltrialsonline.com/view/optimizing-the-process-for-adopting-dct-solutions
September 2022
Tufts CSDD Impact Report: Decentralized and Hybrid Trials Deliver Greater ROI Than Traditional Trials | Ken Getz, Joseph DiMasi, Zachary Smith | Medable
Description: This report from Tufts CSDD assesses the financial impact of decentralized and hybrid clinical trials compared to traditional trials. It provides an analysis of how these trial models deliver greater return on investment, examining the cost-effectiveness, efficiency, and overall outcomes. Read more: https://www.medable.com/knowledge-center/long-form-tufts-impact-report-decentralized-hybrid-trials-deliver-greater-roi-than-traditional-trials
Assessing the Financial Value of Decentralized Clinical Trials | Joseph A. DiMasi, Zachary Smith, Ingrid Oakley‑Girvan, Andrew Mackinnon, Mary Costello, Pamela Tenaerts, Kenneth A. Getz | The Drug Information Association, Inc.
Description: The deployment of remote and virtual clinical trial methods and technologies, referred to collectively as decentralized clinical trials (DCTs), represents a profound shift in clinical trial practice. To our knowledge, a comprehensive assessment of the financial net benefits of DCTs has not been conducted. Tufts CSDD developed an expected net present value (eNPV) model of the cash flows for new drug development and commercialization to assess the financial impact of DCTs. Access the article: https://pmc.ncbi.nlm.nih.gov/articles/PMC9473466/